Kenai Therapeutics

About Kenai Therapeutics

Kenai Therapeutics is a biotechnology company focused on pioneering next-generation approaches to cure neurological conditions. They are advancing off-the-shelf dopamine neuron replacement therapies as disease-modifying and potentially curative treatments for central nervous system conditions like Parkinson's disease, leveraging induced pluripotent stem cell (iPSC) technology to replace neurons lost from neurodegeneration.

Products & Services

RNDP-001:An iPSC dopamine progenitor for the treatment of moderate to severe and inherited forms of Parkinson's disease, showing superior survival, innervation, and behavioral rescue in preclinical models. It is an investigational therapy not yet approved by regulatory authorities.

RNDP-002:A gene-modified iPSC dopamine neuron progenitor targeting mild to severe rapid-progressing Parkinson's disease.

Specialties

Induced Pluripotent Stem Cell (iPSC) Technology Neuron Replacement Therapies Neurological Conditions Treatment Parkinson's Disease Therapy Gene-Modified Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 82000000 MR: - FA: $82 million FAN: 82000000	D: 2024-02-29 FD: 2024-02-29	5 investors

Series A Latest

2024-02-29

$82.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rajesh Mistry

Chief Financial Officer

M

Martin Ostrowski

Chief Legal Officer

D

Derek J. Hei

Chief Technology Officer

Y

Yoshiko Stowell

Vice President of Regulatory Affairs

A

Anton Bittner

Program Director

V

Valeria Yartseva

Director, Preclinical/Translational Biology

View 12 more team members with Pro

Unlock Full Team Directory

Recent News